Degrees of Difficulty

EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.

Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.

The supplemental New Drug Application seeks to expand the use of Ameluz with red light photodynamic therapy beyond the face and scalp to actinic keratoses on the extremities, neck, and trunk.

The 4-day CME meeting in Las Vegas offers up to 24.25 credits and sessions on inflammatory skin disease, skin cancer, pediatric dermatology, aesthetics, and more.

A biopsy-based analysis from the JADE MOA trial presented at EADV 2026 found reductions in pathogenic skin-resident memory T cells alongside restoration of epidermal barrier integrity.

The approval of the oral BTKi rests on a phase 3 result of 29.3% complete response from hives vs 14.0% with placebo at week 12.

This week’s review highlights pediatric oral minoxidil guidance, alopecia areata imaging, inherited skin disorder growth patterns, total-body photography, and radiofrequency microneedling for rosacea.

Celltrion’s US launch of omalizumab-igec adds an interchangeable biosimilar option for eligible patients with chronic spontaneous urticaria.